These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 37301086)

  • 1. Let-7a/cMyc/CCAT1/miR-17-5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1.
    Selem NA; Nafae H; Manie T; Youness RA; Gad MZ
    Pathol Res Pract; 2023 Aug; 248():154579. PubMed ID: 37301086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oleuropin controls miR-194/XIST/PD-L1 loop in triple negative breast cancer: New role of nutri-epigenetics in immune-oncology.
    Hamed MM; Handoussa H; Hussein NH; Eissa RA; Abdel-Aal LK; El Tayebi HM
    Life Sci; 2021 Jul; 277():119353. PubMed ID: 33798547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long noncoding RNA sONE represses triple-negative breast cancer aggressiveness through inducing the expression of miR-34a, miR-15a, miR-16, and let-7a.
    Youness RA; Hafez HM; Khallaf E; Assal RA; Abdel Motaal A; Gad MZ
    J Cell Physiol; 2019 Nov; 234(11):20286-20297. PubMed ID: 30968427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer.
    Mekky RY; Ragab MF; Manie T; Attia AA; Youness RA
    Transl Oncol; 2023 May; 31():101653. PubMed ID: 36907052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis.
    Du C; Wang Y; Zhang Y; Zhang J; Zhang L; Li J
    Cell Transplant; 2020; 29():963689720929983. PubMed ID: 32686982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
    Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
    Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCAT1 promotes triple-negative breast cancer progression by suppressing miR-218/ZFX signaling.
    Han C; Li X; Fan Q; Liu G; Yin J
    Aging (Albany NY); 2019 Jul; 11(14):4858-4875. PubMed ID: 31310241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the lncRNA FGD5-AS1/miR-497-5p/PD-L1 Axis Inhibits Malignant Phenotypes in Colon Cancer (CC).
    Zhang L; Cai X; Dai Y; Chen Y; Yu J; Zhou Y
    Biomed Res Int; 2022; 2022():1133332. PubMed ID: 35845947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA HEIH/miR-939-5p interplay modulates triple-negative breast cancer progression through NOS2-induced nitric oxide production.
    Nafea H; Youness RA; Abou-Aisha K; Gad MZ
    J Cell Physiol; 2021 Jul; 236(7):5362-5372. PubMed ID: 33368266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
    Chen T; Dong Y; Wu X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
    Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
    Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA CCAT1 sponges miR-218-5p to promote EMT, cellular migration and invasion of retinoblastoma by targeting MTF2.
    Meng X; Zhang Y; Hu Y; Zhong J; Jiang C; Zhang H
    Cell Signal; 2021 Oct; 86():110088. PubMed ID: 34265414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
    Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R
    Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YY1-induced long non-coding RNA PSMA3 antisense RNA 1 functions as a competing endogenous RNA for microRNA 214-5p to expedite the viability and restrict the apoptosis of bladder cancer cells via regulating programmed cell death-ligand 1.
    Zhang M; Xu Y; Yin S; Qiu F
    Bioengineered; 2021 Dec; 12(2):9150-9161. PubMed ID: 34720049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment.
    Zhou Y; Yamamoto Y; Takeshita F; Yamamoto T; Xiao Z; Ochiya T
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA SNHG8 enhances triple-negative breast cancer cell proliferation and migration by regulating the miR-335-5p/PYGO2 axis.
    Qian J; Lei X; Sun Y; Zheng L; Li J; Zhang S; Zhang L; Li W; Shi J; Jia W; Tang T
    Biol Direct; 2021 Aug; 16(1):13. PubMed ID: 34362407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer cell-derived exosomal miR-20a-5p inhibits CD8
    Li W; Han G; Li F; Bu P; Hao Y; Huang L; Bai X
    Cancer Sci; 2024 Feb; 115(2):347-356. PubMed ID: 38129137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1.
    Zhang M; Wang N; Song P; Fu Y; Ren Y; Li Z; Wang J
    Cell Prolif; 2020 Sep; 53(9):e12855. PubMed ID: 32687248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect.
    Shi Y; Zhang Y; Ran F; Liu J; Lin J; Hao X; Ding L; Ye Q
    Cancer Lett; 2020 Dec; 495():53-65. PubMed ID: 32946964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA
    Xu YJ; Zhao JM; Ni XF; Wang W; Hu WW; Wu CP
    Epigenomics; 2021 Aug; 13(16):1281-1297. PubMed ID: 34523356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.